Anthem Blue Cross Connecticut Commercial Clinical Policy

TRANS.00034 Hematopoietic Stem Cell Transplantation for Diabetes Mellitus Form

Chat with GenHealth to automate any policy or prior auth task.

Procedure is not covered

Effective Date

01/03/2024

Last Reviewed

11/09/2023

Original Document

Reference

This document addresses the use of hematopoietic stem cell transplantation to reconstitute the immune system as a treatment of diabetes mellitus (DM).

Position Statement

Investigational and Not Medically Necessary:

Autologous or allogeneic (ablative and non-myeloablative) hematopoietic stem cell transplantation is considered investigational and not medically necessary as a treatment of diabetes mellitus.

GenHealth is the best way to run RCM including eligibility, prior auth, billing, and denials with AI that works like a teammate in your EMR and billing systems.

TRANS.00034 Hematopoietic Stem Cell Transplantation for Diabetes Mellitus Form

Procedure is not covered

Position Statement

Choose how you'd like to learn more.

Try GenHealth free.

GenHealth is the best way to run RCM including eligibility, prior auth, billing, and denials with AI that works like a teammate in your EMR and billing systems.

TRANS.00034 Hematopoietic Stem Cell Transplantation for Diabetes Mellitus Form

Procedure is not covered

Position Statement

Choose how you'd like to learn more.

Try GenHealth free.

Automate intake, eligibility, and PA with AI agents that work in your EMR and billing systems.